Therapy Areas: Inflammatory Diseases
Celgene CEO Mark Alles Appointed as Chairman of Board of Directors as Executive Chairman Bob Hugin Retires
31 January 2018 - - Executive chairman Bob Hugin has decided to retire from Summit, New Jersey-based cancer and inflammatory disease treatment developer Celgene Corp. (NASDAQ: CELG) after 19 years of service and to step down from the Celgene board of directors, effective February 5, 2018, the company said.
Chief executive officer Mark Alles has been appointed to the additional role of chairman of the board of directors.
Bob Hugin joined Celgene in 1999 as chief financial officer. He served as president and chief operating officer from 2006 to 2010, and chief executive officer from 2010 until becoming Executive chairman in March 2016. Hugin was elected to serve on the board of directors in December 2001 and became chairman in June 2011.
CEO and newly appointed chairman Mark Alles has been with Celgene since 2004. Prior to becoming CEO in 2016, Mark served as president and COO, and prior to that, as executive vice president and global head of hematology and oncology, helping to build the company's hematology and oncology franchise, as well as various other senior leadership positions.
Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.